Ignite Creation Date:
2024-05-06 @ 9:50 AM
Last Modification Date:
2024-10-26 @ 12:20 PM
Study NCT ID:
NCT03082976
Status:
COMPLETED
Last Update Posted:
2020-07-16
First Post:
2017-02-27
Brief Title:
Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
PREDICT Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region A Prospective Multi-centre Epidemiological Observational Study Designed to Evaluate the Prevalence of BRCA1 and BRCA2 Mutations in Current and Newly Diagnosed Ovarian Cancer Patients Across Different Countries in the Gulf Region This Study Study Will Also Describe the Epidemiological Features for the Disease for the Enrolled Patients
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PREDICT
Brief Summary:
A prospective multi-centre epidemiological observational study designed to evaluate the prevalence of BRCA1 and BRCA2 BReast CAncer gene mutations in current and newly diagnosed ovarian cancer patients across different countries in the Gulf region This study will also describe the epidemiological features for the disease for the enrolled patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None